· Infliximab is human-murine monoclonal antibody that binds to tumour necrosis factor (TNF). 

· An EU marketing authorisation application for the use of infliximab to treat moderately to severe ulcerative colitis (UC) in paediatrics aged 6-17 years of age who have not responded to conventional therapy, was submitted in late 2010.  If approved, infliximab will be the first monoclonal antibody licensed for this indication in paediatrics.

· This review looks at the evidence supporting the use of infliximab to treat UC in paediatrics.